Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Liabilities and Shareholders Equity (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $65.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 29.52% to $65.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299.2 million through Dec 2025, down 30.73% year-over-year, with the annual reading at $84.3 million for FY2025, 31.79% down from the prior year.
  • Liabilities and Shareholders Equity hit $65.1 million in Q4 2025 for Vistagen Therapeutics, down from $80.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $131.1 million in Q4 2023 to a low of $15.0 million in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $77.4 million across 5 years, with a median of $82.6 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 1775.88% in 2021 and later tumbled 74.4% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $90.5 million in 2021, then crashed by 67.19% to $29.7 million in 2022, then skyrocketed by 341.18% to $131.1 million in 2023, then decreased by 29.57% to $92.3 million in 2024, then dropped by 29.52% to $65.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VTGN at $65.1 million in Q4 2025, $80.9 million in Q3 2025, and $68.9 million in Q2 2025.